Education
About Us
Working with TipRanks
Follow Us
Pulse Biosciences (PLSE)
NASDAQ:PLSE
Earnings Data
Report Date
May 07, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.17Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed strong clinical and technology progress—IDE approvals, compelling early efficacy data with high 12‑month success rates, rapid procedure times, and substantial IP expansion—which materially de-risks key scientific and regulatory milestones. However, the financial picture remains early-stage: product revenue is still nominal, gross margin was effectively negligible in the quarter, operating losses persist, cash reserves declined substantially year-over-year, and broader commercialization hinges on additional regulatory clearances and reimbursement processes that may take multiple quarters. Overall, the narrative balances important clinical/strategic momentum against clear near-term financial and commercialization constraints.Company Guidance
Strong Clinical Efficacy in nPulse Electrophysiology Feasibility Studies
European feasibility data presented at AF Symposium: 100% procedural success (6 months) and 96% procedural success (1 year) for evaluable patients; 90% freedom from atrial arrhythmia at 12 months (Kaplan–Meier). Reported routine ablation procedure times of 6–8 minutes (company assertion) with potential to cut total procedure times by over 50% versus legacy approaches.
Multiple IDE Approvals and Pivotal Trial Progress
Company secured IDE approvals for both the electrophysiology catheter (nPulse) and the cardiac surgical clamp (NANOCLAMP AF) and plans to commence and complete nPulse IDE enrollment in 2026 (protocol cited ~155 patients); NANOCLAMP AF pivotal study targets ~136 patients across ~20 sites with enrollment expected to conclude in 2026.
Expanding Intellectual Property Estate
Pulse added 67 issued and 77 pending patents in 2025 (equivalent to ~one new piece of IP every 2.5 days). Total IP: 250 granted patents and ~180 pending patents, strengthening barriers to entry for nsPFA technology.
Vybrance Initial Commercial Traction
Vybrance revenue in Q4 2025 was $264,000 (company described as 'nominal' revenue), up from $86,000 in Q3 2025 — a sequential increase of approximately 207% — driven by both system and disposable (electrode) sales during an intentionally limited launch.
Focused Strategic Partnerships and Regulatory Pathway Planning
Management is actively pursuing mapping and EP ecosystem partnerships to accelerate commercial launch; plans to finalize CE submission for the nPulse catheter in H2 2026 with potential CE Mark in 2027 and intends to file for CE Mark for the surgical clamp by end of 2026.
Operational Discipline and Liquidity Tools
GAAP costs and expenses decreased by $1.7M year-over-year to $18.5M in Q4 2025 (approx. 8% reduction vs prior-year period). Company completed a $200M shelf registration to provide flexibility for financing if needed and stated cash runway to support clinical programs through major 2026 inflection points.
PLSE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PLSE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 19, 2026 | $25.08 | $21.42 | -14.59% |
Nov 05, 2025 | $16.27 | $15.73 | -3.32% |
Aug 12, 2025 | $15.10 | $16.79 | +11.19% |
May 08, 2025 | $16.85 | $17.07 | +1.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pulse Biosciences (PLSE) report earnings?
Pulse Biosciences (PLSE) is schdueled to report earning on May 07, 2026, After Close (Confirmed).
What is Pulse Biosciences (PLSE) earnings time?
Pulse Biosciences (PLSE) earnings time is at May 07, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLSE EPS forecast?
PLSE EPS forecast for the fiscal quarter 2026 (Q1) is -0.27.